Article Sidebar
Views PDF: 183
RESULT OF TREATMENT FIRST-GENERATION TYROSIN KINASE INHIBITORS IN BRAIN METASTASES FROM ADENOCARCINOMA OF THE LUNG WITH EGFR MUTATION
Main Article Content
Abstract
Objectives: Evaluate the result of treatment first-generation tyrosine kinase inhibitors in EGFR positive adenocarcinoma of lung with brain metastases and describe some factors related to PFS. Patients and Methods: 66 patients adenocarcinoma of lung have brain metastasis withEGFR mutations (exon 19 deletion and L858R point mutation exon 21) were treated with Gefitinib 250mg/day or Erlotinib 150mg/day, either whole brain radiation therapy or gamma knife was included or not. Results: The median PFS achieved 11,5 months. The median PFS of TKIs, TKIs + WBRT, TKIs + SRS were 11, 11 and 12,7 months, respectively. The median intracranial PFS was 11 months. Some factors predicts favourable outcomes are exon 19 deletion, response at 3-month and performance stasus 0-1, non or only one organ extracranial metastases. Conclusion: First-generation TKIs for brain metastases in adenocarcinoma of lung with EGFR mutation improved progression-free survival, especially in group used gamma knife in local therapy.
Article Details
Keywords
first-generation TKIs, brain metastases in lung cancer, EGFR mutation
References
2. Tamura, T. et al. Specific organ metastases and survival in metastatic non‑small‑cell lung cancer. Molecular and Clinical Oncology3, 217–221 (2015).
3. Dang, A.-T. H. et al. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Sci Rep10, 2707 (2020).
4. Moumtzi, D. et al. Prognostic factors for long term survival in patients with advanced non-small cell lung cancer. Ann Transl Med4, 161 (2016).
5. Yang, W.-C. et al. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiotherapy and Oncology126, 368–374 (2018).
6. Nguyễn Thị Thanh Huyền, Lê Văn Quảng, Nguyễn Thị Thái Hòa. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ di căn não đột biến EGFR bằng Erlotinib có hoặc không kết hợp với xạ trị tại não, (2018).
7. Magnuson, W. J. et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol35, 1070–1077 (2017).
8. Gerdan, L. et al. Brain metastasis from non-small cell lung cancer (NSCLC): prognostic importance of the number of involved extracranial organs. Strahlenther Onkol190, 64–67 (2014).